Filtered By:
Specialty: Cardiology
Condition: Aortic Stenosis
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 670 results found since Jan 2013.
Comparison of Transcatheter Aortic Valve Replacement between Self-Expanding versus Balloon-Expandable Valves in Patients with Small Aortic Annulus
CONCLUSIONS: TAVR with self-expanding valves was associated with superior hemodynamic outcomes compared with balloon-expandable valves in patients with small aortic annulus.PMID:33655721 | PMC:PMC7925971 | DOI:10.4070/kcj.2020.0409
Source: Korean Circulation Journal - March 3, 2021 Category: Cardiology Authors: Yong Joon Lee Seung Jun Lee Sung Jin Hong Chi Young Shim Chul Min Ahn Jung Sun Kim Byeong Keuk Kim Geu Ru Hong Young Guk Ko Donghoon Choi Yangsoo Jang Myeong Ki Hong Source Type: research
Impact of the Trifecta bioprosthetic valve in patients with low-flow severe aortic stenosis
This study aimed to evaluate the effect of the Trifecta bioprosthesis, which has a large effective orifice area, in patients with low-flow severe AS who have a poor prognosis. We retrospectively evaluated 94 consecutive patients with severe AS who underwent aortic valve replacement (AVR). Patients were divided into two groups according to the stroke volume index (SVI): low-flow (LF) group (SVI < 35 ml/m2,n = 22) and normal-flow (NF) group (SVI ≥ 35 ml/m2,n = 72). Patients’ characteristics and early and mid-term results were compared between the two groups. There were no differences in patients’...
Source: Heart and Vessels - February 14, 2021 Category: Cardiology Source Type: research
Two-year outcomes from the PARTNER 3 trial: where do we stand?
Purpose of review
The PARTNER 3 trial was conducted to compare outcomes after transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve and surgical aortic valve replacement (SAVR) in individuals at low surgical risk with aortic stenosis. Recently reported rates of death, stoke and valve thrombosis in the TAVR arm have raised concerns about the longevity of this intervention in low-risk individuals. It is incumbent on all members of the Heart Team to understand the potential consequences of these findings.
Recent findings
TAVR was initially superior to SAVR at 1 year for a primary composite e...
Source: Current Opinion in Cardiology - February 12, 2021 Category: Cardiology Tags: VALVULAR HEART DISEASE: Edited by Subodh Verma and Bobby Yanagawa Source Type: research
TAVR in nonagenarians: An analysis investigating safety, efficacy, symptomatic improvement, and long-term survival.
CONCLUSIONS: Out of 2336 patients, 2183 were younger than 90 years (<90y.-group) and 153 patients were aged 90 or older (≥90y.-group). Procedure-related mortality (3.6% <90y.-group vs. 3.3% ≥90y.-group, log-rank p=0.9) and device success (97.2% <90y.-group vs. 96.0% ≥90y.-group, p=0.44) were similar. Estimated survival rates at 2 years were 62.8% (95% CI 55.3 and 71.4) in the elder and 76.0% (95% CI 74.1 and 77.8) in the younger patients (p<0.01). The incidence of acute kidney injury, stroke, major bleeding, and permanent pacemaker implantations were comparable between both groups. TAVR procedure is equal...
Source: Journal of Cardiology - February 6, 2021 Category: Cardiology Authors: Zadrozny M, Hainzer N, Mehilli J, Jochheim D, Gschwendtner S, Steffen J, Theiss H, Braun D, Hagl C, Sadoni S, Massberg S, Hausleiter J, Deseive S Tags: J Cardiol Source Type: research
Prognostic value of the H2FPEF score in patients undergoing transcatheter aortic valve implantation
ConclusionsThe H2FPEF score serves as an independent predictor of adverse CV and heart failure outcome among TAVI patients with preserved EF. A high H2FPEF score is associated with the presence of paradoxical low ‐flow, low‐gradient AS, the HFpEF in patients with AS. By identifying patients in advanced stages of HFpEF, the H2FPEF score might be useful as a risk prediction tool in patients with preserved EF scheduled for TAVI.
Source: ESC Heart Failure - January 25, 2021 Category: Cardiology Authors: Sebastian Ludwig,
Costanza Pellegrini,
Alina Gossling,
Tobias Rheude,
Lisa Voigtl änder,
Oliver D. Bhadra,
Matthias Linder,
Daniel Kalbacher,
Benedikt Koell,
Lara Waldschmidt,
Johannes Schirmer,
Moritz Seiffert,
Hermann Reichenspurner,
Stefa Tags: Original Research Article Source Type: research
Fabry disease in cardiology: Diagnosis and therapeutic approaches
Turk Kardiyol Dern Ars. 2020 Dec;48(Suppl 2):1-42. doi: 10.5543/tkda.2020.38262.ABSTRACTFabry disease is a rare, progressive, X-linked inherited storage disorder due to absent or deficient of lysosomal alfa galactosidase A activity. Deficient activity of alfa-galactosidase A results in progressive accumulation of globotriaosylceramide in a variety of tissues and organs including myocardium, kidney and nerve system. This disorder predominantly affects males; however, female heterozygotes may also be affected with a less severe clinical picture. Classic Fabry disease is usually diagnosed in early age of childhood because of ...
Source: Turk Kardiyoloji Dernegi arsivi - January 21, 2021 Category: Cardiology Authors: Y üksel Çavuşoğlu Ebru Özpelit Nur Arslan Mesut Demir G ökhan Kahveci H üseyin Onay Emir Özgür Barış Ökçün Oma ç Tufekcioglu Selcen Yakar T ülüce Gonca K ılıç Yıldırım Source Type: research
